According to GlobalData’s company profile on Zydus Lifesciences, NSAID cancer drugs was a key innovation area identified from patents. Zydus Lifesciences's grant share as of February 2024 was 71%.
U.S. annual sales for Baclofen Oral Suspension total approximately $39 million, according to IQVIA data. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified ...
BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the ...
Former Bartholomew County Prosecutor Bill Nash’s law license will be suspended for 30 days, the Indiana Supreme Court has ruled in resolving his attorney discipline case. Nash’s suspension ...
The recall involves Lot #AW0221A with an expiration date of August 2025. AvKARE, LLC is recalling 1 lot of Atovaquone Oral Suspension, USP 750 mg/5 mL due to the potential for microbial contamination ...
US Food and Drug Administration. AvKARE, LLC. issues voluntary nationwide recall of Atovaquone Oral Suspension, USP 750 mg/5 mL due to potential Bacillus cereus contamination. April 1, 2024.
AvKARE, LLC. is voluntarily recalling lot # AW0221A of Atovaquone Oral Suspension, USP 750mg/5mL to the Consumer/User level, due to the potential Bacillus cereus contamination in the product found ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results